HealthNewsAPI
Personalized Vaccine For 'Deadliest Major Cancer' Keeps Patients Alive 6 Years Later - ScienceAlert
Overview
Researchers presented data showing an experimental personalized vaccine for pancreatic cancer produced longer-term survival, with some patients still alive six years after treatment. The new daraxonrasib results add a complementary therapeutic advance, illustrating that both immune-based vaccines and targeted drugs may improve outcomes for some patients. Both approaches remain early and will require broader validation, comparative trials, and expanded access before they change population-level outcomes.
Entities
ORGScienceAlertLOCUnited States
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 7 · Connections: 6
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.